UPLOAD Filing
Spyre Therapeutics, Inc.
Date: Feb. 25, 2026 · CIK: 0001636282 · Accession: 0000000000-26-001931
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293600
Letter
February 25, 2026 Cameron Turtle Chief Executive Officer Spyre Therapeutics, Inc. 221 Crescent Street Building 23, Suite 105 Waltham, MA 02453 Re:Spyre Therapeutics, Inc. Registration Statement on Form S-3 Filed February 19, 2026 File No. 333-293600 Dear Cameron Turtle: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Thomas Danielski, Esq.
Show Raw Text
February 25, 2026
Cameron Turtle
Chief Executive Officer
Spyre Therapeutics, Inc.
221 Crescent Street
Building 23, Suite 105
Waltham, MA 02453
Re:Spyre Therapeutics, Inc.
Registration Statement on Form S-3
Filed February 19, 2026
File No. 333-293600
Dear Cameron Turtle:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Thomas Danielski, Esq.